Co-development for advanced companion diagnostics (CDx)
At Protagen, we are highly committed to in-depth profiling of patients’ immune responses using multi-parameter autoantibody signatures for patient stratification, to enable effective prognosis, prediction of therapy response, and the development of companion diagnostics (CDx). Such tests can be applied at different stages in the clinical development pipeline:
- Co-development of CDx starting with Phase I/II clinical trials
- Development of CDx after regulatory approval and market entry
We are actively involved in customized CDx programs for pharmaceutical and biotechnology companies of all sizes. These are structured as collaborative projects and strategic alliances. We offer our technology and in-depth scientific know-how for biomarker programs covering autoimmunity and other areas, to yield safer drugs for improved, personalized treatment.